SLC5A2 and type 2 diabetes mellitus: In addition, the relationships between SGLT-2 inhibitors, including canagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin and tofogliflozin, and loss of weight in T2DM patients, were shown in formulas (11)–(16), respectively:(11)EFF=−3.72%×Time3.35+Time,(12)EFF=−5.59%×Time16.8+Time,(13)EFF=−2.84%×Time3.42+Time,(14)EFF=−3.43%×Time3.09+Time,(15)EFF=−3.04%×Time4.38+Time,(16)EFF=−2.45%×Time3.16+Time.